Technical Confluences:
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
- Price is in Oversold Conditions in D1 timeframe
- Price action bouncing off 150% Fibo Extension
- Price is trying to go back above the Interest Zone to give some bullish momentum to the stock
Fundamental Confluences:
-Regardless how bad the negative rumours are ongoing about the side-effects from Pfizer; they are still considered a strong market leader in the Pharma industry
- They had a good response on a testing of their recent respiratory drug
- Value?
----
Health sector in your Portfolio will never be wrong with the global aging population.
I am putting this trade on as either into my Long-Term Portfolio or Swing trade for $PFE.
Depending on how market develops, I may decide to hold this bag and allocate more into it at the 178% Fibo Extension levels or cut my Buy position as shown.
-----
Disclaimer: The personal opinion above does not constitute as an investment advice. Any trade decisions taken based on the above opinion is purely at your own risks. DYOR.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
Disclaimer: The personal opinion above does not constitute as an investment advice. Any trade decisions taken based on the above opinion is purely at your own risks. DYOR.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。